ClinConnect ClinConnect Logo
Search / Trial NCT06254950

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Launched by TAKEDA · Feb 2, 2024

Trial Information

Current as of August 22, 2025

Recruiting

Keywords

Drug Therapy Latitude Uc, Latitude Research Program

ClinConnect Summary

This clinical trial is studying a new medication called TAK-279 to see if it can help reduce inflammation in the bowels of people with moderately to severely active ulcerative colitis (UC). The main goal is to determine if TAK-279 is more effective than a placebo, which is an inactive treatment. Participants will take either TAK-279 or a placebo for up to 3 months, and then everyone will receive TAK-279 for an additional year. Throughout the study, participants will visit the clinic several times to monitor their health and any side effects.

To participate in the trial, individuals need to be between 18 and 75 years old and have been diagnosed with UC for at least 30 days. They must also have experienced insufficient relief from previous treatments. However, people with certain other types of bowel diseases or serious complications from UC, like strictures or the need for surgery, cannot join. This study is currently looking for participants, and by joining, they will contribute to important research that could improve treatment for ulcerative colitis.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Male or female aged 18-75 years old with diagnosis of UC for at least 30 days. In South Korea, the age requirement for adult participants is ≥19 years of age.
  • 2. Confirmed diagnosis of moderately to severely active UC assessed by mMS and ES.
  • 3. Participants with a history of inadequate response to, loss of response to, or intolerance to one or more of conventional, biologic or advance therapies for UC.
  • 4. Participants must meet the contraception recommendations.
  • Exclusion Criteria:
  • 1. Participants with indeterminate/unclassified inflammatory bowel disease (IBD), microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, diverticular disease associated with colitis, and/or clinical/histologic findings suggestive of Crohn's disease (CD).
  • 2. Participants with complications of UC such as strictures, stenoses, fistulas, short gut syndrome, or any other manifestation that might require surgery during the study.
  • 3. Participants with a current ileostomy or colostomy. Participants who had a J-pouch are excluded, as a J-pouch could result in a stoma.
  • 4. Participants who have failed 3 or more classes of advanced therapies.

About Takeda

Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical organization committed to advancing patient care through innovative therapies. Founded in 1781 and headquartered in Osaka, Japan, Takeda focuses on key therapeutic areas including oncology, gastroenterology, neuroscience, and rare diseases. With a strong emphasis on research and development, Takeda leverages cutting-edge science and technology to deliver transformative medicines that address unmet medical needs. The company is dedicated to sustainability and ethical practices, ensuring that its clinical trials uphold the highest standards of safety and efficacy while fostering collaboration with healthcare professionals and communities worldwide.

Locations

Heidelberg, Victoria, Australia

Tilburg, , Netherlands

Perth, Western Australia, Australia

Aalborg, , Denmark

Heraklion, Crete, Greece

Paris, , France

Seattle, Washington, United States

Louisville, Kentucky, United States

Huelva, , Spain

Melbourne, Victoria, Australia

Bedford Park, South Australia, Australia

Woodville, South Australia, Australia

Tuebingen, , Germany

Basel, , Switzerland

Sapporo, Hokkaido, Japan

Seoul, , Korea, Republic Of

Kaohsiung, , Taiwan

Seoul, , Korea, Republic Of

Sakura, Chiba, Japan

Chengdu, Sichuan, China

Lorenskog, Akershus, Norway

London, Ontario, Canada

New Westminster, British Columbia, Canada

Taichung City, , Taiwan

Leuven, , Belgium

Jerusalem, , Israel

Decatur, Georgia, United States

Wuhan, Hubei, China

Tianjin, Tianjin, China

Shanghai, Shanghai, China

Budapest, , Hungary

Changsha, Hunan, China

Rome, , Italy

Fukuoka, , Japan

Frankfurt Am Main, , Germany

Calgary, Alberta, Canada

Budapest, , Hungary

Seoul, , Korea, Republic Of

Saga, , Japan

Athens, , Greece

Vac, , Hungary

Minato Ku, Tokyo, Japan

Hradec Kralove, , Czechia

Tyler, Texas, United States

Fuenlabrada, , Spain

Palermo, , Italy

Los Angeles, California, United States

Tampa, Florida, United States

London, Ontario, Canada

Daegu, , Korea, Republic Of

Nedlands, Western Australia, Australia

North Massapequa, New York, United States

Koge, , Denmark

Banska Bystrica, , Slovakia

Busan, , Korea, Republic Of

Seoul, , Korea, Republic Of

Busan, , Korea, Republic Of

Brno, , Czechia

Changhua City, Changhua County, Taiwan

Seoul, , Korea, Republic Of

Patras, Achaia, Greece

Mohacs, , Hungary

Las Vegas, Nevada, United States

Wuhan, Hubei, China

Sydney, New South Wales, Australia

Brno, , Czechia

Praha 5, , Czechia

Warsaw, , Poland

Atlanta, Georgia, United States

Daegu, , Korea, Republic Of

Murrieta, California, United States

Glen Burnie, Maryland, United States

Belfast, , United Kingdom

Sofia, , Bulgaria

Ashdod, , Israel

Lakeland, Florida, United States

Seoul, , Korea, Republic Of

Miami Lakes, Florida, United States

Szczecin, Zachodniopomorskie, Poland

London, Greater London, United Kingdom

Houston, Texas, United States

Madrid, , Spain

Sofia, , Bulgaria

Ceske Budejovice, , Czechia

Montreal, Quebec, Canada

Mannheim, , Germany

Zamosc, , Poland

Bydgoszcz, Kujawsko Pomorskie, Poland

Liberty, Missouri, United States

Shanghai, Shanghai, China

Orange, California, United States

Iowa City, Iowa, United States

Clermont Ferrand, , France

Providence, Rhode Island, United States

Lodz, , Poland

Greenville, South Carolina, United States

Changzhou, Jiangsu, China

Bucharest, , Romania

Cambridge, , United Kingdom

Milan, , Italy

Gdynia, Pomorskie, Poland

Kiel, , Germany

Hannover, , Germany

Warsaw, , Poland

Clearwater, Florida, United States

Naples, Florida, United States

New York, New York, United States

Bellaire, Texas, United States

Heidelberg, , Germany

Rozzano, , Italy

Tampa, Florida, United States

Oklahoma City, Oklahoma, United States

Brussels, Anderlecht / Region Capitale De Bruxelles/ Brussel, Belgium

Montreal, Quebec, Canada

Ostrava Poruba, , Czechia

Praha, , Czechia

Odense, Syddanmark, Denmark

Esbjerg, , Denmark

Hillerod, , Denmark

Hvidovre, , Denmark

Neuilly Sur Seine, , France

Nice Cedex 3, , France

Saint Etienne, , France

Vandoeuvre Les Nancy, , France

Hamburg, , Germany

Ludwigshafen, , Germany

Ulm, , Germany

Athens, Attiki, Greece

Athens, , Greece

Budapest, , Hungary

Bologna, , Italy

Hirakata, Osaka, Japan

Minato, Tokyo, Japan

Mitaka City, Tokyo, Japan

Wonju, Gangwon, Korea, Republic Of

Drammen, Gjettum, Norway

Oslo, , Norway

Tromso, , Norway

Wroclaw, Dolnolskie, Poland

Wroclaw, Dolnoslaskie, Poland

Torun, Kujawsko Pomo, Poland

Warszawa, Mazowieckie, Poland

Lodz, , Poland

Lublin, , Poland

Rzeszow, , Poland

Rzeszow, , Poland

Timisoara, Jud Timis, Romania

Bucharest, , Romania

Bucharest, , Romania

Bucuresti, , Romania

Bratislava, , Slovakia

Kosice, , Slovakia

Nove Zamky, , Slovakia

London, E1 2at, United Kingdom

London, , United Kingdom

Seoul, , Korea, Republic Of

Kingswood, New South Wales, Australia

Melbourne, Victoria, Australia

Halifax, Nova Scotia, Canada

Guangzhou, Guangdong, China

Shenyang, Liaoning Sheng, China

Shanghai, , China

Chambray Les Tours, , France

Amsterdam, , Netherlands

Lodz, Lodzkie, Poland

Tychy, , Poland

Wroclaw, , Poland

Taipei City, Zhongzheng District, Taiwan

Taoyuan City, , Taiwan

Guangzhou, , China

Hangzhou, , China

Zhejiang, , China

Murdoch, Western Australia, Australia

Vaughan, Ontario, Canada

Shenzhen, Gangdong, China

Shijiazhuang, Hebei Sheng, China

Tianjin, Jiangsu, China

Ostrava Poruba, , Czechia

Nice Cedex 3, , France

Vandoeuvre Les Nancy, , France

Rome, , Italy

Torino, , Italy

Oslo, , Norway

Bucuresti, , Romania

Banska Bystrica, , Slovakia

Murdoch, , Australia

Sliven, , Bulgaria

South Brisbane, Queensland, Australia

Epping, , Australia

Plovdiv, , Bulgaria

Sofia, , Bulgaria

Horovice, Stredocesky, Czechia

Brno, , Czechia

Ostrava, , Czechia

Pardubice, , Czechia

Usti Nad Labem, , Czechia

Beer Sheva, , Israel

Ramat Gan, , Israel

Sahy, , Slovakia

Sofia, , Bulgaria

Sofia, , Bulgaria

Chongqing, Chongqing Sheng, China

Prague 5, , Czechia

Bucuresti, , Romania

Guangzhou, Guangdong, China

Kaohsiung, Zhongzheng District, Taiwan

London, , United Kingdom

Taipei City, Zhongzheng District, Taiwan

Brussels, , Belgium

Patients applied

0 patients applied

Trial Officials

Study Director

Study Director

Takeda

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported